canada clinical guidance

Familial hypercholesterolaemia (FH)

A Canadian clinical summary of familial hypercholesterolaemia (fh), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by 2021 guidelines for the management of dyslipidemia for cardiovascular disease prevention. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CCS lipids

Source-attributed clinical priorities

  • Suspect familial hypercholesterolemia from markedly elevated LDL cholesterol, premature atherosclerotic disease and family history.
  • Exclude important secondary causes while beginning guideline-directed lipid lowering when the phenotype is convincing.
  • Arrange family cascade assessment and specialist input according to provincial genetic and lipid-clinic pathways.
  • Use a validated clinical diagnostic approach and document the pedigree across multiple generations.
sources for this section:CCS lipids

Practical assessment and management workflow

1
Repeat a fasting or nonfasting lipid profile and exclude hypothyroidism, nephrotic, hepatic and medication causes.
2
Assess premature coronary disease, tendon xanthomas and first-degree family lipid and event history.
3
Begin intensive LDL-lowering and refer for lipid-specialist or genetic assessment where available.
4
Arrange cascade screening and follow response and adherence longitudinally.
sources for this section:CCS lipids

Safety, red flags and urgent escalation

  • Do not delay treatment solely because genetic testing is unavailable or negative.
  • Address pregnancy planning because lipid-lowering medicines have different reproductive safety.
  • Escalate children and severe phenotypes through a specialist family-lipid pathway.
sources for this section:CCS lipids

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CCS lipids

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CCS lipids

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Cardiovascular Society2021 guidelines for the management of dyslipidemia for cardiovascular disease preventionaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.